source
- Boston Scientific lowers full-year revenue outlook as restructuring plan targets slowing growthBoston Scientific announced on July 29 that it is cutting its 2026 full-year organic revenue growth forecast to 5-6%, down from the prior 6.5-8% range. The revision follows a second consecutive qu…
- FDA releases FY 2027 user fee rates for prescription, generic, biosimilar, device and over the counter programsThe U.S. Food and Drug Administration has published its user fee schedule for fiscal year 2027. The rates cover prescription drugs, generic drugs, biosimilars, medical devices and over the counter…